

Interim report 3 2019 Invent Medic Sweden AB

CEO Karin Bryder summarizes the quarter

During the third quarter of 2019, we have spent a lot of time on preparing the launches of efemia in the UK and Germany which are taking place now in the fourth quarter. Among other things, we have delivered the first product orders. At the same time, we continue our marketing of efemia in Sweden, where several regions in the healthcare sector finally initiated relevant procurement processes in which we participate with efemia. During the quarter, we also participated in the International Continence Society's (ICS) annual meeting in Gothenburg. There was a great interest in efemia, and we met several exciting persons and entities to follow up going forward. In addition, the scientific lectures pointed out the importance of products such as efemia, both in general as a complement to surgery as well as for specific women's groups. One of these groups is women who are engaged in "high impact" activities such as gym exercise, a segment that we are now looking more closely at. efemia has already been proven as a very suitable product for gym exercise. In two recent studies, all participants were helped by the product. We are also progressing with our evaluations of additional promising potential vaginal health products, as we see great potential in expanding our product portfolio as our distribution network for efemia is expanded to additional and larger markets.

Results in brief

KSEK	2019 July - Sept	2018 July - Sept	2019 July - Sept	2018 July - Sept	2018 July - Dec
Sales income	31	0	248	0	41
Other operating income	0	84	0	445	444
Operating costs	-2 875	-2 537	-9 207	-7 048	-9 795
Result for the period	-2 844	-2 453	-8 960	-6 604	-9 311

For more information please contact

Karin Bryder, CEO

Phone: +46 (0)723811710

E-mail: info@inventmedic.com

About Invent Medic

Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women's health and quality of life. The company's products are to be safe, effective and easy to use. The finished women's health products are sold through the company's Arcamea brand. Invent Medic's first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic's share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share's ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.